CSS
MRKR icon

Cubist Systematic Strategies’s Marker Therapeutics MRKR Stock Holding History

Cubist Systematic Strategies’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,734
Closed -$132K – 3090
2021
Q2 		$132K Sell
4,734
-2,464
-34% -$64.9K ﹤0.01% 2677
2021
Q1 		$161K Buy
+7,198
New +$165K ﹤0.01% 2540
2019
Q3 		– Sell
-2,293
Closed -$182K – 2373
2019
Q2 		$182K Buy
+2,293
New +$136K ﹤0.01% 2083

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Cubist Systematic Strategies's MRKR Position: Q3 2021 in Review

Cubist Systematic Strategies sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 4,734 shares — an estimated $132K sold.

Cubist Systematic Strategies first reported a position in MRKR in Q2 2019 and held it in 3 quarters. The position peaked at $182K in Q2 2019. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

  • Cubist Systematic Strategies reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cubist Systematic Strategies sold 4,734 Marker Therapeutics shares in Q3 2021, an estimated $132K.
  • Cubist Systematic Strategies first reported a position in Marker Therapeutics in Q2 2019 and held it in 3 quarters.
  • Cubist Systematic Strategies's Marker Therapeutics position peaked at $182K in Q2 2019.
  • 63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on Cubist Systematic Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.